Eli Lilly’s stock has swum on Alzheimer’s drug developments. What investors need to know.
Text size Eli Lilly’s headquarters in Indianapolis Jonathan Weiss / Bruadar When Eli Lilly they presented the results of a small study on donanemab therapy Alzheimer’s disease last weekend, i…
